Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeLatest newsA message from Chairman and CEO Alex Gorsky about Johnson & Johnson’s investigational COVID-19 vaccine candidate
      lede-A Message from Chairman and CEO Alex Gorsky About Johnson & Johnson's Investigational COVID-19 Vaccine Candidate.jpg

      A message from Chairman and CEO Alex Gorsky about Johnson & Johnson’s investigational COVID-19 vaccine candidate

      The company leader shares the latest news about topline results from the Phase 3 clinical trial for its single-dose investigational COVID-19 vaccine candidate.

      Share Article
      share to

      One year ago this week, Johnson & Johnson pledged that we would leverage all of our capabilities to fight an emerging threat, then being referred to as simply “the novel coronavirus.” Since then, we have focused our efforts on delivering a single-dose vaccine that would be a safe, effective and efficient solution for the largest number of people around the world.

      I couldn’t be more proud—or grateful—to share that we have made a significant step towards reaching our ambitious goal.

      Today, we shared positive topline Phase 3 clinical trial results for our single-dose investigational COVID-19 vaccine candidate. We will continue to work with health authorities around the world on regulatory applications.

      Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic.

      COVID-19 has touched the lives of every person on this planet and tested us as a society and as individuals. But Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic. Our work on an investigational COVID-19 vaccine will be an enduring point of pride for us for decades to come.

      Doing our part to combat the greatest public health crisis in living memory has been a huge undertaking for our company. I owe a deep debt of gratitude to the incredible teams that made this milestone a reality, and to each and every one of my 135,000 colleagues for living into Our Credo values with great resilience and agility to ensure we keep meeting the healthcare needs of all who rely on Johnson & Johnson.

      COVID-19 continues to inflict heartbreak and hardship, and there is still much that must be done to bring this pandemic to an end. But I am more optimistic than ever that these dark days are numbered.

      I hope that our announcement today serves as a welcome reminder of the transformative power of science, the multiplying effect of collaboration and—most of all—the possibility of a better, healthier future.

      Stay Up to Date on Johnson & Johnson’s Janssen COVID-19 Vaccine

      See answers to frequently asked questions, learn about the company’s innovative vaccine technology platform and more.
      A close-up view of the novel coronavirus

      More from Johnson & Johnson

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.